Last reviewed · How we verify
serologic response evaluation
At a glance
| Generic name | serologic response evaluation |
|---|---|
| Sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Affordable Made-in-India Microspheres for Liver Cancer Therapy (PHASE1)
- Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses (NA)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- Open-Label Influenza Vaccine Evaluation (NA)
- Randomized Influenza Vaccine Evaluation of Immune Response (PHASE4)
- Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster. (PHASE2, PHASE3)
- 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies (PHASE2)
- UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: